Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic, described in the open access journal BMC Infectious Diseases found that it was only capable of identifying 50.7% of TB cases.
Klaus Reither led a team of researchers from the Ludwig-Maximilians-University of Munich, Germany, the University College London, UK, and the NIMR-Mbeya Medical Research Programme, Tanzania, who tested LAM-ELISA in 291 Tanzanian patients suspected of having TB. He said, "Only 35 out of 69 pulmonary TB cases, confirmed by smear microscopy and/or solid culture and/or liquid culture, showed at least one positive LAM-ELISA result. This 50.7% sensitivity of the LAM-ELISA was disappointingly low. The specificity of 87.8 % also fell far short of expectations".
Novel approaches are urgently needed to improve TB diagnosis and control. The LAM-ELISA detects lipoarabinomannan (LAM), a mycobacterium-specific lipopolysaccharide component of the bacilli's cell wall. In active mycobacterial disease, LAM is released into the blood and passes the renal barrier without major changes – suggesting that its detection in urine should be a reliable diagnostic indicator. Urine can be easily obtained and its collection is often more culturally accepted than the collection of sputum or blood samples.
Although this particular test did not fulfill the requirements for a stand-alone diagnostic test for pulmonary tuberculosis, the researchers speculate that it may still be of some use, "In our opinion, further investigations are needed to elucidate if the LAM-ELISA, in this stage of development, is valuable as a supplemental tool for the diagnosis of HIV-associated TB. This seems particularly important, when taking into consideration that TB is one of the most important opportunistic infections of HIV patients and that the sensitivity of smear microscopy in immunocompromised patients is low".
Notes to Editors
1. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis
Klaus Reither, Elmar Saathoff, Jutta Jung, Lilian T Minja, Inge Kroidl, Eiman Saad, Jim F Huggett, Elias N Ntinginya, Lucas Maganga, Leonard Maboko and Michael Hoelscher
BMC Infectious Diseases (in press)
During embargo, article available here: http://www.biomedcentral.com/imedia/2420794842689915_article.pdf?random=803281
After the embargo, article available at journal website: http://www.biomedcentral.com/bmcinfectdis/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at email@example.com on the day of publication
2. BMC Infectious Diseases is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Infectious Diseases (ISSN 1471-2334) is indexed/tracked/covered by PubMed, MEDLINE, CAS, Scopus, EMBASE, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.